The biology of ovarian cancer: New opportunities for translation

Robert C. Bast, Bryan Hennessy, Gordon B. Mills

    Research output: Contribution to journalReview articlepeer-review

    921 Scopus citations


    Over the past two decades, the 5-year survival for ovarian cancer patients has substantially improved owing to more effective surgery and treatment with empirically optimized combinations of cytotoxic drugs, but the overall cure rate remains approximately 30%. Many investigators think that further empirical trials using combinations of conventional agents are likely to produce only modest incremental improvements in outcome. Given the heterogeneity of this disease, increases in long-term survival might be achieved by translating recent insights at the molecular and cellular levels to personalize individual strategies for treatment and to optimize early detection.

    Original languageEnglish (US)
    Pages (from-to)415-428
    Number of pages14
    JournalNature Reviews Cancer
    Issue number6
    StatePublished - Jun 2009

    ASJC Scopus subject areas

    • Oncology
    • Cancer Research

    Fingerprint Dive into the research topics of 'The biology of ovarian cancer: New opportunities for translation'. Together they form a unique fingerprint.

    Cite this